secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001213900-22-058902
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics appoints Jerry McLaughlin to Board of Directors, effective Oct 1, 2022
--------------------------------------------------------------------------------

- Jerry McLaughlin appointed as Class II director, expanding board from six to seven members.
- McLaughlin qualifies as independent director under NASDAQ rules; serves on Audit and Compensation Committees.
- Compensation: $50k annual cash retainer, $7.5k Audit Committee fee, and options for 23k shares vesting over 36 months.
- McLaughlin is CEO of Life Biosciences, former CEO of Neos Therapeutics and AgeneBio; 30 years biopharma experience.
- Press release and updated company overview presentation furnished as Exhibits 99.1 and 99.2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/0001213900-22-058902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/ea166296-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-058902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer